Iradimed (IRMD) Cash & Equivalents (2013 - 2026)

Iradimed (IRMD) has 14 years of Cash & Equivalents data on file, last reported at $56.4 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 12.01% year-over-year to $56.4 million in Q1 2026; TTM through Mar 2026 was $56.4 million, a 12.01% increase from a year earlier, with the FY2025 full-year figure at $51.2 million, down 2.06% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $56.4 million, up from $51.2 million in the prior quarter.
• Over the last five years, Cash & Equivalents for IRMD reached as high as $58.0 million in Q4 2022 and fell as low as $42.8 million in Q1 2023.
• Historically, Cash & Equivalents has averaged $51.0 million across 5 years, with a median of $51.2 million in 2025.
• Across the five-year window, Cash & Equivalents decreased 15.91% in 2023 and grew 12.01% in 2026, its largest moves.
• Year by year, Cash & Equivalents stood at $58.0 million in 2022, then decreased by 14.15% to $49.8 million in 2023, then advanced by 4.97% to $52.2 million in 2024, then retreated by 2.06% to $51.2 million in 2025, then rose by 10.19% to $56.4 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $56.4 million in Q1 2026, $51.2 million in Q4 2025, and $56.5 million in Q3 2025.